225 results on '"Kanzler, Stephan"'
Search Results
2. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
3. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
4. Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial
5. Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
6. Adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction – A multicenter phase I/II feasibility study (GMBH-STO-0114)
7. Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114).
8. Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
9. Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
10. Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
11. Alternating application of gemcitabine/ nab -paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the...
12. Integrated Analysis of the RASH Study with the Use of the 'Burden of Therapy' (BOTh®TM) Methodology : A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
13. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh ®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.
14. AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC.
15. Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer – Data From a Randomized German Phase II Trial
16. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients
17. Apoptose in der Klinik
18. Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis
19. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice
20. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma
21. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis
22. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
23. Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.
24. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
25. Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?
26. Incidence of HAV and HBV Infections and Vaccination Rates in Patients With Autoimmune Liver Diseases
27. Five Cases of De Novo Inflammatory Bowel Disease After Orthotopic Liver Transplantation
28. Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors
29. Budesonide in previously untreated autoimmune hepatitis
30. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure
31. Duration of immunosuppressive therapy in autoimmune hepatitis
32. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
33. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis
34. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
35. Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).
36. Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).
37. Su1129 – Predictive Significance of Endosonographic (EUS) Staging in Locally Advanced Gastric (GC) Or Gastroesophagealjunction (AEG) Adenocarcinoma: Analysis of Data from a Perioperative Aio-Cao Phase Ii Study
38. Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity
39. A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer
40. Predictive Significance of endosonographic (EUS) Staging in locally advanced gastric Adenocarcinoma of the Stomach (MC) or esophagogastric Junction (AEG)-Analysis of Data from a perioperative AIO-CAO Phase II Study
41. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
42. FOLFOXIRI Plus Panitumumab As First-Line Treatment of Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
43. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).
44. Stellenwert der perioperativen Chemotherapie mit ECX /- Panitumumab bei lokal fortgeschrittenen ösophagogastralen Adenokarzinomen: Eine randomisierte Studie der AIO und der DGAV
45. Additional file 2: of Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
46. Additional file 1: of Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
47. FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis
48. Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX.
49. Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.
50. “CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.